GOAL MD Review: Flat-Dose Pricing and Pharmacy Disclosure

What FDA oversight does and does not establish

"Only FDA-monitored 503A/B pharmacies."

It sits on the homepage (as of August 2026), under a heading that reads "LegitScript Certified".

FDA does oversee compounders. State boards generally handle day-to-day oversight of state-licensed pharmacies that are not outsourcing facilities; FDA also performs surveillance and for-cause inspections. Registered 503B outsourcing facilities are primarily overseen by FDA and inspected on a risk-based schedule. Compounded drugs are not FDA-approved. ⁷

Adjacent to it: "Safe, legal, properly compounded medications." That is a conclusion. What sits under it now is a three-word badge — "Third-party quality testing" — with no laboratory, no assay, no lot number and no certificate.

The odd part is that the correct sentence is on the same page. GOAL MD's footer now carries a genuine compounding disclosure it did not carry a fortnight ago:

"Compounded medications are personalized formulations prepared by licensed U.S. 503A or 503B compounding pharmacies based on a physician's prescription… Compounded medications are not FDA-approved."

Those statements need not contradict each other: oversight and drug approval are different. But the FDA-monitored phrase alone does not certify a facility or a product. A named facility would let a patient check relevant licensing, registration and inspection records; FDA cautions that outsourcing registration does not mean approval or compliance. ⁸

It is not claim-free

GOAL MD does assert outcomes.

Six testimonials on the homepage carry pound figures — −70, −57, −50, −45, and one at −175. The coaching panel makes the most specific claim on the site:

"15+ lbs additional weight loss with coaching … Based on meta-analysis of randomized controlled trials, eClinicalMedicine 2025"

A journal and a year, with no title, no authors and no identifier. That is a citation shaped like a citation, and a reader cannot follow it.

Inside the intake — a hosted flow whose text does not appear in the page's own body copy — the second screen asserts that "Research shows that 80% of people are more attracted to those with leaner, stronger appearances" and that "Over 90% of patients report higher self-confidence after achieving visible weight loss results." Neither carries any source.

The trials behind semaglutide and tirzepatide are real. ^{1 2} None of the three sentences above is drawn from them.

The peptides, graded

GOAL MD's navigation now carries a Peptides column, and it sells Sermorelin "for muscle support & recovery" at $179 a month on a three-month charge and NAD+ "for energy and longevity" at $249 a month, both marked Rx only. The intake's first question offers "Muscle & Recovery — Sermorelin peptide therapy" and "Energy & Longevity — NAD+ therapy" as alternatives to weight loss. Both are graded above; here is what the searching actually turned up.

The sermorelin count that means nothing

Search ClinicalTrials.gov for sermorelin and you get 21 completed studies. That number is worthless, and the reason is worth a paragraph.

Open all 21 and read the field that records what participants were actually given. Nine of them administered tesamorelin or TH9507 — a different molecule, in HIV patients. Several used unspecified "GHRH" as a diagnostic stimulation test, which is a fifteen-minute procedure to see whether a pituitary responds, not a treatment. One used full-length GHRH 1-44, one a long-acting growth hormone, one octreotide. Not one of the 21 gave anybody sermorelin. ³

The published literature is thinner still, and its trap is the opposite one. Searching PubMed for sermorelin restricted to randomized controlled trials returns 19 records — but restrict that same search to the title and abstract and it returns zero, because the trial literature calls the molecule GHRH(1-29)-NH2 and almost never prints the brand name. This site has published a correction about exactly that error before, and it is the reason the number above is 19 and not nothing.

What the closest trial actually measured

Of those 19, three touch anything GOAL MD sells this for. One is about galanin in Cushing's disease. One measured hormone levels in old men. The third is the trial that matters, from 1997: nineteen adults aged 55 to 71, self-injecting nightly for sixteen weeks against placebo. ⁴

Read its results against the product page, line by line:

That is a more interesting result than a bare absence, and it cuts both ways. The claim GOAL MD words most cautiously is the one the evidence best supports. The claim it states flatly in its benefits list rests on nine men in a study from 1997. And the sleep promise is not merely untested — it was measured, and it was not found.

One caveat this review will not skip, because it is the same kind of care this page is asking of GOAL MD: the 1997 trial used a norleucine-substituted GHRH(1-29) analog, not sermorelin itself. It is the nearest evidence there is. It is not evidence about this exact molecule, because there isn't any.

NAD+ at $249 a month

The most expensive product GOAL MD sells month to month — more than a month of semaglutide or tirzepatide on any term — and the one with the least behind it.

Four randomized trials in the literature mention NAD+ with an injected route. One of them actually gives it, in heart failure caused by ischemic cardiomyopathy. The other three are a phase 1 trial of a different compound, a hypertonic-saline heart-failure study, and a paper about how fast blood clears alcohol. ^{5 6}

The page is worth reading closely for how it moves between registers. "NAD+ is a coenzyme present in every living cell" — true. "Research shows NAD+ levels tend to decline as we age" — true. "NAD+ therapy is designed to help replenish this essential coenzyme" — a statement about intent. And then a three-stage timeline in which "many patients report steadier daytime energy and improved mental clarity" by weeks 2 to 4. Each sentence is defensible on its own; the sequence delivers a reader to a conclusion nobody measured.

The part GOAL MD gets right, on the same site

Its peptides section is genuinely good, and saying so is not a courtesy. Twenty ingredient pages, each physician- and compliance-reviewed with named reviewers and a review date, plus a separate listing that labels each substance's regulatory status: tesamorelin, oxytocin and PT-141 as "FDA-approved for a specific indication", and BPC-157, CJC-1295, ipamorelin, MOTS-c, epitalon, TB-500 and eleven others as "Investigational". Its own usage notes warn that regulatory labels are per ingredient and must not be rolled up into a claim of FDA approval, and state plainly: "Compounded preparations are not FDA-approved."

That is better regulatory writing than this review has found anywhere else in the category, and it sits on the same domain as a badge reading "FDA-monitored 503A/B pharmacies".

Two gaps in it, though. Nothing in that section can be ordered — it is explicitly education-only — so a reader who arrives at the product pages never meets it. And sermorelin is not one of the twenty. GOAL MD publishes a reviewed evidence page for nineteen peptides it does not sell and none for the one it does.

What is missing

No pharmacy named. No certificate of analysis.

On states, GOAL MD gives a number and not a list. Click the FAQ accordion open and it says:

"We currently serve patients in 48 states across the US… Contact us to confirm availability in your specific state."

Forty-eight means two are excluded. Neither the forty-eight nor the two is named, there is no state checker, and the answer is behind a closed accordion rather than on the page. This review names no excluded states, because naming them would mean inventing them — not because none exist, since the count says two do.

One thing the accordions do answer well: "Are medications included in my treatment plan?" gets "Yes! All of our treatment plans include your prescribed medications, physician consultations, ongoing monitoring, and free expedited shipping directly to your door. There are no hidden fees or additional pharmacy costs." That is the all-inclusive claim stated plainly, and it matches the ladders.